Paclitaxel

製品コードS1150 別名:NSC 125973

Paclitaxel化学構造

分子量(MW):853.91

Paclitaxelは一種microtubulポリマー(polymer)安定剤で、人間内皮細胞の中にIC50値が0.1 pMです。

サイズ 価格(税別) 在庫  
JPY 15106.00 あり
JPY 11620.00 あり
JPY 44820.00 あり

カスタマーフィードバック(4)

  • Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

    ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.

    Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

    RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

  • Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

    Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.

    Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

    PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.

製品安全説明書

Microtubule Associated阻害剤の選択性比較

生物活性

製品説明 Paclitaxelは一種microtubulポリマー(polymer)安定剤で、人間内皮細胞の中にIC50値が0.1 pMです。
ターゲット
Microtubule (human endothelial cells) [1]
0.1 pM
体外試験

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LBe2lEPTB;MD6wNFAzQDdizszN NX3MSVg3W0GQR1XS
LC-2-ad MlvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwMECwN|E4KM7:TR?= NXn3RZhbW0GQR1XS
RL95-2 MmW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwMECwOlY5KM7:TR?= NWLvOVlNW0GQR1XS
MZ1-PC MmSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTBwMECwO|I6KM7:TR?= NUGy[Hd5W0GQR1XS
TE-8 NEG4ZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LodmlEPTB;MD6wNFEyPyEQvF2= M4Lke3NCVkeHUh?=
SW954 M13mdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwMECxNVkh|ryP M3LPTnNCVkeHUh?=
TE-11 NHPTc|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXL6d2o2UUN3ME2wMlAxOTJ|IN88US=> NFXQZ2dUSU6JRWK=
PSN1 MoDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMECxN{DPxE1? NYjCOnFFW0GQR1XS
MOLT-4 M{DiUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX2zTG95UUN3ME2wMlAxOTR7IN88US=> M{TYU3NCVkeHUh?=
697 M3K0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrCO2x5UUN3ME2wMlAxOTVizszN NFLsbHZUSU6JRWK=
ETK-1 NW[xZ|JlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV64eIlIUUN3ME2wMlAxOTV{IN88US=> M3vndXNCVkeHUh?=
TE-10 M{jRNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zxXmlEPTB;MD6wNFE2PCEQvF2= M4rD[XNCVkeHUh?=
HUTU-80 NXnFfnlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDLTWM2OD1yLkCwNVY5KM7:TR?= MUHTRW5ITVJ?
NTERA-S-cl-D1 NETscFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPucoxWUUN3ME2wMlAxOjB7IN88US=> MYfTRW5ITVJ?
MFH-ino Moj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLTTWM2OD1yLkCwNlY5KM7:TR?= NIrSUnZUSU6JRWK=
IA-LM NFL2fHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVi0SlB7UUN3ME2wMlAxOjhizszN MV\TRW5ITVJ?
MC116 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rIfGlEPTB;MD6wNFI5QSEQvF2= M{HOT3NCVkeHUh?=
RKO NEjzUGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PB[2lEPTB;MD6wNFI6QCEQvF2= MXjTRW5ITVJ?
MRK-nu-1 MmmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwMECyPVkh|ryP M{ewcXNCVkeHUh?=
VA-ES-BJ NEPOeYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2naO2lEPTB;MD6wNFMh|ryP NXWxcnBEW0GQR1XS
KALS-1 MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInuSoFKSzVyPUCuNFA{ODhizszN MmXpV2FPT0WU
BB30-HNC M1XCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwMECzNVQh|ryP NYSyOHROW0GQR1XS
ACN MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTmPINLUUN3ME2wMlAxOzF4IN88US=> MUfTRW5ITVJ?
TE-9 NIrpdllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwMECzNlYh|ryP MVvTRW5ITVJ?
SIG-M5 NX3XXnZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVj3Zo14UUN3ME2wMlAxOzJ5IN88US=> NGj1W25USU6JRWK=
no-10 M2nJVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7VUoRKSzVyPUCuNFA{PjJizszN NEDVXYZUSU6JRWK=
EW-1 M1HmPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV33SoxEUUN3ME2wMlAxOzdzIN88US=> M3j4RnNCVkeHUh?=
SK-LMS-1 NGPT[nlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD3TWM2OD1yLkCwOFAyKM7:TR?= MVTTRW5ITVJ?
GT3TKB MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrUbYNKSzVyPUCuNFA1OzRizszN NXi2bFhoW0GQR1XS
ES4 NVPYVmNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwMEC0OFkh|ryP MmTKV2FPT0WU
IMR-5 M1zu[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDnc|l[UUN3ME2wMlAxPDVizszN NYrOV2JIW0GQR1XS
NCI-H1648 MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUL6[FlzUUN3ME2wMlAxPDZ7IN88US=> MWrTRW5ITVJ?
MV-4-11 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnXTWM2OD1yLkCwOFc2KM7:TR?= M1LlVHNCVkeHUh?=
SK-UT-1 NIPZPGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PHdGlEPTB;MD6wNFQ5KM7:TR?= Mo\LV2FPT0WU
NB13 MkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[0TWlEPTB;MD6wNFQ6OSEQvF2= NFrNZ5FUSU6JRWK=
DJM-1 NYntV|I1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwMEC1N{DPxE1? MYTTRW5ITVJ?
ES8 M3;Nb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XP[WlEPTB;MD6wNFU{QCEQvF2= NU\Lc3U1W0GQR1XS
TE-6 MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LmXmlEPTB;MD6wNFU4KM7:TR?= M{PqNHNCVkeHUh?=
KS-1 NXjS[49OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwMEC1PFIh|ryP Mlu1V2FPT0WU
TE-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnUT3VKSzVyPUCuNFA3ODZizszN MYjTRW5ITVJ?
ATN-1 MnvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3POUmlEPTB;MD6wNFYxQSEQvF2= M4S0O3NCVkeHUh?=
A4-Fuk NYfPVphsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPzTWM2OD1yLkCwOlEyKM7:TR?= MUPTRW5ITVJ?
ALL-PO Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fXSWlEPTB;MD6wNFY{KM7:TR?= NU\1Z2p6W0GQR1XS
BE-13 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml2zTWM2OD1yLkCwOlM3KM7:TR?= MY\TRW5ITVJ?
KM12 M4HoXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\RSmZKSzVyPUCuNFA3OzdizszN NUHQUIU4W0GQR1XS
NOS-1 M{jWR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwMEC2OUDPxE1? MVXTRW5ITVJ?
SW962 NULRRVVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwMEC2OlIh|ryP MYTTRW5ITVJ?
OCUB-M M1zrWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjvTWM2OD1yLkCwOlYzKM7:TR?= MV7TRW5ITVJ?
NCI-H510A MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nUTGlEPTB;MD6wNFY3PSEQvF2= NW\NU49WW0GQR1XS
EW-16 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLCTWM2OD1yLkCwOlk1KM7:TR?= NFHFXlBUSU6JRWK=
KGN MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwMEC3NVIh|ryP MYTTRW5ITVJ?
LS-411N NXfhfVBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Ta[WlEPTB;MD6wNFcyPyEQvF2= MWnTRW5ITVJ?
Becker NVu3UFJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{T0dWlEPTB;MD6wNFczKM7:TR?= Ml;NV2FPT0WU
HC-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXUVWNKSzVyPUCuNFA4OjFizszN M{\ydHNCVkeHUh?=
CESS NGfhTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;ZTWM2OD1yLkCwO|M4KM7:TR?= M4XwSnNCVkeHUh?=
KURAMOCHI NXH2Z4hqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGmxNoRKSzVyPUCuNFA4PDhizszN M{Xye3NCVkeHUh?=
TGBC24TKB NFSzSXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorVTWM2OD1yLkCwO|UzKM7:TR?= NVnmTGl1W0GQR1XS
SW982 MnXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf4TWM2OD1yLkCwO|Y3KM7:TR?= NUXWcYV2W0GQR1XS
HCE-4 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMEC3Olch|ryP MVzTRW5ITVJ?
LOUCY MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF:2XlFKSzVyPUCuNFA4PzVizszN MUTTRW5ITVJ?
8-MG-BA MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTBwMEC3PVYh|ryP Mlm3V2FPT0WU
HT-144 M2TFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMEC4JO69VQ>? MWfTRW5ITVJ?
LXF-289 MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwMEC4NVgh|ryP MlfSV2FPT0WU
RS4-11 NWLOc283T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwMEC4N|Yh|ryP NV3nOWEzW0GQR1XS
DEL MnmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwMEC4OFUh|ryP NU\Me|lnW0GQR1XS
OCI-AML2 NH7tOnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\VbVZKSzVyPUCuNFA5PTJizszN M2Lz[nNCVkeHUh?=
CCRF-CEM MmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwMEC4O|Eh|ryP MmDVV2FPT0WU
A388 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;wb2lEPTB;MD6wNFg4PCEQvF2= NF\6V3FUSU6JRWK=
KNS-42 MonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWe3PGV1UUN3ME2wMlAxQDlzIN88US=> MUXTRW5ITVJ?
OVCAR-4 NVrwfmlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2K5UGlEPTB;MD6wNFkxPCEQvF2= NV;LXIJnW0GQR1XS
NCI-H1355 NVz3RYhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITy[|JKSzVyPUCuNFA6OTRizszN M37HcXNCVkeHUh?=
BL-70 NIjSfHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwMEC5N{DPxE1? MkCwV2FPT0WU
BL-41 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LiTWlEPTB;MD6wNFk{PCEQvF2= M2\5ZXNCVkeHUh?=
A101D NUXBPVRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfLRY1VUUN3ME2wMlAxQTZizszN NFPrPG9USU6JRWK=
HL-60 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NID3PIRKSzVyPUCuNFA6PjZizszN M4O2eXNCVkeHUh?=
COR-L279 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfPTWM2OD1yLkCwPVk6KM7:TR?= M3fJXHNCVkeHUh?=
NCI-SNU-16 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{j1bmlEPTB;MD6wNVAxQCEQvF2= MVPTRW5ITVJ?
Calu-6 NGT5XJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4frZ2lEPTB;MD6wNVAyOiEQvF2= MUjTRW5ITVJ?
SR NHHaU|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTkTWM2OD1yLkCxNFI3KM7:TR?= NV\Mc2xtW0GQR1XS
QIMR-WIL M4L0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvkW3BTUUN3ME2wMlAyODN|IN88US=> NV3rd|ROW0GQR1XS
LB647-SCLC NF2zTnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n6TmlEPTB;MD6wNVA2OSEQvF2= NGTpb|lUSU6JRWK=
RPMI-8226 M{\tSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELUb3FKSzVyPUCuNFEyODJizszN MYrTRW5ITVJ?
SK-PN-DW NYL5eXRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDrSIZYUUN3ME2wMlAyOTF{IN88US=> NUK4ZXFlW0GQR1XS
SF268 M{XES2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jk[mlEPTB;MD6wNVE2OSEQvF2= NHvvW2lUSU6JRWK=
HD-MY-Z NXraO2xuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1T6Z2lEPTB;MD6wNVE3OyEQvF2= MlnWV2FPT0WU
DOHH-2 NVnFeIJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXNTWM2OD1yLkCxNlA{KM7:TR?= M{\FTHNCVkeHUh?=
SCC-3 M2r5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NED0O2lKSzVyPUCuNFEzODRizszN MmDHV2FPT0WU
ST486 NVjtemVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwMEGyNFQh|ryP M{PtXHNCVkeHUh?=
NALM-6 NETW[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjHUohKSzVyPUCuNFEzOTRizszN MonQV2FPT0WU
NCI-H1436 M{T3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwMEGyN|Eh|ryP M3:wZnNCVkeHUh?=
KE-37 NGPjWldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfqRXJKSzVyPUCuNFEzOzRizszN MVPTRW5ITVJ?
RPMI-8402 NICxO5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\ETWM2OD1yLkCxNlU3KM7:TR?= NWHlWWhVW0GQR1XS
RXF393 M4PnTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDWTWM2OD1yLkCxNlU4KM7:TR?= NFXMNopUSU6JRWK=
KARPAS-45 M4fVTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHvTnlKSzVyPUCuNFEzPyEQvF2= MVrTRW5ITVJ?
HOP-62 M3nJdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwMEGyO|Yh|ryP NFHoe4JUSU6JRWK=
ES1 MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmL2TWM2OD1yLkCxNlg5KM7:TR?= NIjYSGhUSU6JRWK=
L-363 MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3mOpMzUUN3ME2wMlAyOzVzIN88US=> NUnWe|FRW0GQR1XS
GI-1 NVfUTnJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFqzTmRKSzVyPUCuNFE{PzNizszN NWnLfXN4W0GQR1XS
CTV-1 MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2riSmlEPTB;MD6wNVQ4QCEQvF2= MmHJV2FPT0WU
TE-5 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDKTWM2OD1yLkCxOFk3KM7:TR?= MYPTRW5ITVJ?
SNU-C2B MlHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jkc2lEPTB;MD6wNVQ6PiEQvF2= NGXub2NUSU6JRWK=
K-562 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HFTGlEPTB;MD6wNVUyPiEQvF2= NXPuW4JjW0GQR1XS
SNB75 M3Xvd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mor4TWM2OD1yLkCxOVQh|ryP NXP2b|ZLW0GQR1XS
MOLT-13 NF;R[WhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzrTWM2OD1yLkCxOlM4KM7:TR?= NFjjbFFUSU6JRWK=
LS-123 MmLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYH2eXB1UUN3ME2wMlAyPjZ2IN88US=> M2fR[3NCVkeHUh?=
NCI-SNU-5 Mo\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwMEG3NFEh|ryP MVjTRW5ITVJ?
Daudi M1rlPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrMcm1KSzVyPUCuNFE4ODhizszN NVi5NJVsW0GQR1XS
A253 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXu5OGxwUUN3ME2wMlAyPzN6IN88US=> NYHXcoNOW0GQR1XS
TGBC1TKB Mmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\xTWM2OD1yLkCxO|UzKM7:TR?= NX\Cd4dXW0GQR1XS
SJSA-1 Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4WzemlEPTB;MD6wNVc3PyEQvF2= Mk\WV2FPT0WU
NCCIT M{Dvd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LWVWlEPTB;MD6wNVc3QSEQvF2= NIPENIRUSU6JRWK=
NCI-H69 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;FTWM2OD1yLkCxO|c5KM7:TR?= NY\xbZVwW0GQR1XS
SH-4 M2nx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXsTWM2OD1yLkCxPFk2KM7:TR?= MoXKV2FPT0WU
HCC1187 M1HpTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO0cVJyUUN3ME2wMlAyQTJ2IN88US=> NWLleZVVW0GQR1XS
HCC1599 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHscI5KSzVyPUCuNFIxOiEQvF2= M1nwV3NCVkeHUh?=
ONS-76 M1riOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjNXXBiUUN3ME2wMlAzODN4IN88US=> MWjTRW5ITVJ?
KU812 M2\3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXPWpRKSzVyPUCuNFIxOzlizszN NEfQdIFUSU6JRWK=
ML-2 MmDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonKTWM2OD1yLkCyNFQ4KM7:TR?= NVrKVGg4W0GQR1XS
HCE-T MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fMdWlEPTB;MD6wNlA6OiEQvF2= M{HrfXNCVkeHUh?=
NCI-H446 NXHCTnhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwMEKxNVIh|ryP MkfpV2FPT0WU
RPMI-6666 NHzIcZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwMEKxOFkh|ryP NEXESohUSU6JRWK=
MOLT-16 M2PhVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFW3fIFKSzVyPUCuNFIyPTNizszN MYnTRW5ITVJ?
JiyoyeP-2003 NELkNXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPvTWM2OD1yLkCyNVc3KM7:TR?= M3TmUXNCVkeHUh?=
MHH-PREB-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjWRlVKSzVyPUCuNFIyQTFizszN MXvTRW5ITVJ?
MC-CAR Mnf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwMEKzNlYh|ryP NVS4b5hTW0GQR1XS
BC-3 M3rWbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGK5[2ZKSzVyPUCuNFI{PDRizszN NGS1U5FUSU6JRWK=
KINGS-1 M4PX[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrKe2pKSzVyPUCuNFI{PTVizszN MW\TRW5ITVJ?
PF-382 MmLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfvOVZKSzVyPUCuNFI{PzhizszN M4S5e3NCVkeHUh?=
J-RT3-T3-5 NXnUd4ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3naZ2lEPTB;MD6wNlM5OyEQvF2= NIjjbXFUSU6JRWK=
SF539 M1:3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\kXFNKSzVyPUCuNFI1ODFizszN MV\TRW5ITVJ?
LB831-BLC MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PHOGlEPTB;MD6wNlQ5PSEQvF2= MnnaV2FPT0WU
DMS-114 MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LPeWlEPTB;MD6wNlUxOiEQvF2= NX\4[IdXW0GQR1XS
LB1047-RCC Ml;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX24emh2UUN3ME2wMlAzPTFizszN MnHhV2FPT0WU
LB771-HNC Mm\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rqb2lEPTB;MD6wNlU{PCEQvF2= M1z4O3NCVkeHUh?=
BB65-RCC Moi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TGW2lEPTB;MD6wNlU{PCEQvF2= MlPNV2FPT0WU
BV-173 NUPRO5BDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTBwMEK1OVQh|ryP MWnTRW5ITVJ?
ARH-77 Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE[1T5pKSzVyPUCuNFI3ODFizszN NGO4XZhUSU6JRWK=
IST-MEL1 NH;WWG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlT5TWM2OD1yLkCyOlI{KM7:TR?= MWrTRW5ITVJ?
NB1 M{PiU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUf6bpJSUUN3ME2wMlAzPjh5IN88US=> NHnadoNUSU6JRWK=
EoL-1-cell Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfQN5VKSzVyPUCuNFI3QDhizszN NFryenBUSU6JRWK=
KY821 M3PDVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTBwMEK2PVch|ryP MXTTRW5ITVJ?
CMK NVTPZmpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwMEK3N|Qh|ryP Ml\zV2FPT0WU
NCI-H2126 NGD0PWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDuRW1KSzVyPUCuNFI4PjhizszN M4OyUXNCVkeHUh?=
NCI-H526 NVnjXo8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Tu[GlEPTB;MD6wNlg6OSEQvF2= M1j4[nNCVkeHUh?=
COLO-684 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPkfFdKSzVyPUCuNFI6ODhizszN MorWV2FPT0WU
NCI-H747 MlzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUW5cFl[UUN3ME2wMlAzQTN|IN88US=> MojVV2FPT0WU
JAR MlvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nLUGlEPTB;MD6wNlk1PiEQvF2= MU\TRW5ITVJ?
MEG-01 M1HyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHWemcxUUN3ME2wMlAzQTd6IN88US=> Mk\FV2FPT0WU
MONO-MAC-6 NFHKT5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXtTWM2OD1yLkCzNFI{KM7:TR?= MVPTRW5ITVJ?
IST-SL1 M1uwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEj1VZRKSzVyPUCuNFMxPDJizszN NED1[ZhUSU6JRWK=
CPC-N NHK2TmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGC4clhKSzVyPUCuNFMxPzlizszN MWDTRW5ITVJ?
NCI-H1963 NUnNdWpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVizNZJUUUN3ME2wMlA{OTNzIN88US=> NEXMdnlUSU6JRWK=
K052 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TFU2lEPTB;MD6wN|I1PyEQvF2= NYrPVm1pW0GQR1XS
KM-H2 M4nkemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLSXGxiUUN3ME2wMlA{OzB5IN88US=> NVPDU4xWW0GQR1XS
TE-12 NUn5cXo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFG5fY5KSzVyPUCuNFM{ODlizszN NGXISXZUSU6JRWK=
TK10 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwMEOzOVYh|ryP M{G0SnNCVkeHUh?=
NMC-G1 NGfaTXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\oRWZKSzVyPUCuNFM1PTJizszN NI\adIJUSU6JRWK=
no-11 NWWyUnlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMEO0O|gh|ryP M3vkUHNCVkeHUh?=
NCI-H524 Ml7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3JTWM2OD1yLkCzOVI6KM7:TR?= NWnn[I5LW0GQR1XS
MHH-CALL-2 Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvr[GRuUUN3ME2wMlA{PTZ{IN88US=> MWnTRW5ITVJ?
GB-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHpR2JOUUN3ME2wMlA{PiEQvF2= NWjSSXFMW0GQR1XS
OPM-2 NXnCPXpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Hw[mlEPTB;MD6wN|Y4OyEQvF2= NF7hUIVUSU6JRWK=
RH-1 NYXpToFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTBwMEO4NVkh|ryP M2K1SXNCVkeHUh?=
NCI-H64 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnntTWM2OD1yLkCzPFU4KM7:TR?= MYfTRW5ITVJ?
EVSA-T MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTCTWM2OD1yLkCzPVI{KM7:TR?= Mo\0V2FPT0WU
KARPAS-299 NFLqeZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTZTWM2OD1yLkCzPVgh|ryP NVv6dVBUW0GQR1XS
MZ7-mel M2TEeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUGzXWRxUUN3ME2wMlA1ODRizszN MkHBV2FPT0WU
LB373-MEL-D NVLXUXJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwMESxNFUh|ryP M1fmT3NCVkeHUh?=
HEL MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXewWphyUUN3ME2wMlA1OTRizszN MVXTRW5ITVJ?
SW872 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TpZ2lEPTB;MD6wOFIyKM7:TR?= MUDTRW5ITVJ?
DU-4475 M17OPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwMESyOFQh|ryP NEO0UZNUSU6JRWK=
IST-SL2 NVm2PVZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLDdXNKSzVyPUCuNFQzPzVizszN M1XnOHNCVkeHUh?=
NCI-H82 NULpPHlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13qeGlEPTB;MD6wOFMxPyEQvF2= MmT2V2FPT0WU
LC4-1 NUK2RYdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMESzOVEh|ryP MnvmV2FPT0WU
HDLM-2 M3GzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwMESzPVIh|ryP NGjXPZBUSU6JRWK=
MMAC-SF NVrJ[lNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjSdZg1UUN3ME2wMlA1PTN2IN88US=> MoS0V2FPT0WU
L-540 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMES2N|kh|ryP MXTTRW5ITVJ?
MZ2-MEL M1LJRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjvfpNTUUN3ME2wMlA1PzR{IN88US=> MoXLV2FPT0WU
LU-134-A Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwMES3O|Mh|ryP M3LMT3NCVkeHUh?=
UACC-257 MoLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;LZ|RKSzVyPUCuNFQ5PDlizszN M{TRfnNCVkeHUh?=
NCI-H1581 NELWU5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjie2JNUUN3ME2wMlA1QTV|IN88US=> MXnTRW5ITVJ?
NB17 NFnsU4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjtU|VwUUN3ME2wMlA1QTd7IN88US=> NUD4OoE1W0GQR1XS
SBC-1 MmfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHOWplIUUN3ME2wMlA2ODR{IN88US=> NH:zTmJUSU6JRWK=
TALL-1 NHj3XpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLB[ZFKSzVyPUCuNFUxPDVizszN MXzTRW5ITVJ?
NCI-H1304 NWC1e5RRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV74[FZHUUN3ME2wMlA2OjB6IN88US=> NW\oTppOW0GQR1XS
NEC8 MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzsT49KSzVyPUCuNFUzQDZizszN Mn7iV2FPT0WU
CAL-148 NH\vT4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\zTWM2OD1yLkC1OFM6KM7:TR?= M4[xSXNCVkeHUh?=
CGTH-W-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGGweIhKSzVyPUCuNFU1PDlizszN M4ribnNCVkeHUh?=
NCI-H889 NXvZZ|BMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3iwSmlEPTB;MD6wOVU6OiEQvF2= M2rq[XNCVkeHUh?=
GR-ST MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHjRmFTUUN3ME2wMlA2PjJzIN88US=> MXHTRW5ITVJ?
KARPAS-422 NGLJN|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILXT3NKSzVyPUCuNFU3PSEQvF2= M1TQPXNCVkeHUh?=
RPMI-8866 NEHs[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmC5TWM2OD1yLkC1O|EzKM7:TR?= Mlz4V2FPT0WU
SCLC-21H NUP3[G1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nLN2lEPTB;MD6wOVg5PCEQvF2= NVHCUJFZW0GQR1XS
COR-L88 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvYOFNKSzVyPUCuNFU6OjdizszN NWSxOnhZW0GQR1XS
LU-139 NUDCNpY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPqTWM2OD1yLkC1PVg3KM7:TR?= M1;oRnNCVkeHUh?=
SF126 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV63epNLUUN3ME2wMlA3OTN|IN88US=> MnPFV2FPT0WU
NCI-H1882 NXPHcY84T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPvTHlWUUN3ME2wMlA3PDJ2IN88US=> MUXTRW5ITVJ?
EW-24 NEHj[5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfvRYhKSzVyPUCuNFY1QDNizszN NVjhS|RXW0GQR1XS
CP67-MEL M{Xjfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XjO2lEPTB;MD6wOlgyKM7:TR?= MVXTRW5ITVJ?
DG-75 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;kTWM2OD1yLkC2PFk6KM7:TR?= MnzNV2FPT0WU
LOXIMVI Ml72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwMEewNlgh|ryP MmexV2FPT0WU
HH NHyyS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LtbGlEPTB;MD6wO|E2PyEQvF2= Moi0V2FPT0WU
K5 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUCwSWtnUUN3ME2wMlA4OjJ4IN88US=> NFLTPWxUSU6JRWK=
EC-GI-10 NE\ieZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV[4bJhEUUN3ME2wMlA4OjV5IN88US=> NVzI[2RRW0GQR1XS
SK-N-DZ M1;JXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwMEezNFch|ryP MVzTRW5ITVJ?
A3-KAW Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrleFlKSzVyPUCuNFc{PTFizszN M1i3SnNCVkeHUh?=
MLMA Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknVTWM2OD1yLkC3OFY2KM7:TR?= NGfQWJpUSU6JRWK=
LB996-RCC MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrPSmFRUUN3ME2wMlA4PzB5IN88US=> MYrTRW5ITVJ?
OS-RC-2 NGTCb4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPFNpVKSzVyPUCuNFc4PDhizszN Mkf2V2FPT0WU
CTB-1 M4HkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3y5b2lEPTB;MD6wO|gyKM7:TR?= NXHYdIZxW0GQR1XS
IST-MES1 MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2f0OmlEPTB;MD6wO|kyOiEQvF2= MnjmV2FPT0WU
LS-1034 MmnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfzTWM2OD1yLkC4NFM2KM7:TR?= MYfTRW5ITVJ?
HT M2jrd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37ENGlEPTB;MD6wPFA5PiEQvF2= NVzxPJhDW0GQR1XS
NCI-H2141 MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfrTWM2OD1yLkC4NUDPxE1? NU\2cnM5W0GQR1XS
LB2518-MEL MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4L1UGlEPTB;MD6wPFE1OSEQvF2= NHHnOpNUSU6JRWK=
GI-ME-N M2npSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwMEi0OVIh|ryP MX3TRW5ITVJ?
TGW MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDoTWM2OD1yLkC4OlA4KM7:TR?= NF71WGlUSU6JRWK=
SK-NEP-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIT1e4dKSzVyPUCuNFg3PDFizszN MmTGV2FPT0WU
NOMO-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HKS2lEPTB;MD6wPVI4PSEQvF2= Mnm4V2FPT0WU
ES6 NX3pR29DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwMEm1PFkh|ryP NI\2[W9USU6JRWK=
NCI-H209 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwMEm3PFYh|ryP M{P5U3NCVkeHUh?=
GAK MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvJOJhKSzVyPUCuNVAyPiEQvF2= MWPTRW5ITVJ?
BC-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnGyTWM2OD1yLkGwN|YyKM7:TR?= MWLTRW5ITVJ?
KLE M4HoNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3OxbmlEPTB;MD6xNFQ1OyEQvF2= MmrVV2FPT0WU
EW-3 MnT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3GTWM2OD1yLkGwPVgh|ryP M3TqWXNCVkeHUh?=
NKM-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrRTWM2OD1yLkGxNUDPxE1? Mk[4V2FPT0WU
D-336MG NIjHNmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rxVGlEPTB;MD6xNVI1PCEQvF2= NHTLSIpUSU6JRWK=
NB69 Mlq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHWT3BKUUN3ME2wMlEyOzBzIN88US=> M4rsS3NCVkeHUh?=
D-263MG NV;Kepg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH4XZEyUUN3ME2wMlEyPzF{IN88US=> MnzuV2FPT0WU
KP-N-YS M3vx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzXe|RKSzVyPUCuNVIzQTFizszN MYfTRW5ITVJ?
NCI-H1155 MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zoTWlEPTB;MD6xNlU2QCEQvF2= NXLkV45ZW0GQR1XS
BOKU NIHRPHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn2wTWM2OD1yLkGyOVc6KM7:TR?= NVj2WWdzW0GQR1XS
LAMA-84 NHS0UplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFGzO49KSzVyPUCuNVI6QSEQvF2= NU\WbnN4W0GQR1XS
Raji Mn3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnaeFBVUUN3ME2wMlE{OTF5IN88US=> MV3TRW5ITVJ?
LU-65 M2nQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\ReYtnUUN3ME2wMlE{OzB5IN88US=> MnHoV2FPT0WU
NCI-H187 MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLDTWM2OD1yLkGzPVI1KM7:TR?= MVrTRW5ITVJ?
GCIY MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NESyUmdKSzVyPUCuNVQ6ODFizszN M4i4SnNCVkeHUh?=
NCI-H2107 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwMUWwPEDPxE1? M{XhOnNCVkeHUh?=
NCI-H1522 NUnTbXNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIX2SmJKSzVyPUCuNVUzPjZizszN NHHLPGlUSU6JRWK=
NB6 NVfzfldYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWGxU2E6UUN3ME2wMlE2PjJ|IN88US=> NILTT|lUSU6JRWK=
EM-2 M2PpfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPITWM2OD1yLkG1O|A3KM7:TR?= NUXyTXVuW0GQR1XS
HCC2218 NFS1N2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwMUW5PEDPxE1? NWDxNY5SW0GQR1XS
NCI-H748 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXFXFZKSzVyPUCuNVY{PzZizszN MVzTRW5ITVJ?
MS-1 Moi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHxRllKSzVyPUCuNVY2OzdizszN MlzrV2FPT0WU
NB5 MmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwMU[1PVch|ryP NV7TXWx4W0GQR1XS
OMC-1 NVn2V5k1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvXXXdxUUN3ME2wMlE3Pjh6IN88US=> M3XvUnNCVkeHUh?=
NCI-H345 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwMU[5Nlgh|ryP MlvSV2FPT0WU
L-428 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrtTWM2OD1yLkG2PVQ2KM7:TR?= NF7McoxUSU6JRWK=
SCH Mkn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLTcZFKSzVyPUCuNVg3QDVizszN NGHLRoRUSU6JRWK=
NCI-H1417 M2DWdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XZSWlEPTB;MD6xPVIzPyEQvF2= NV\VWG0yW0GQR1XS
COLO-320-HSR NVvoVZpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrLSlFoUUN3ME2wMlE6PTN{IN88US=> MVLTRW5ITVJ?
BT-474 NHHEdGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1riVGlEPTB;MD6yNFg6OiEQvF2= M4\CeXNCVkeHUh?=
GDM-1 NGXQNo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\OTnVKSzVyPUCuNlE6PzFizszN NF3rbGxUSU6JRWK=
NCI-H2196 M3XUPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXyeXZKSzVyPUCuNlIzOzVizszN NXLQZZF6W0GQR1XS
KP-N-RT-BM-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3yXIF[UUN3ME2wMlIzOzR7IN88US=> NUO1N5NCW0GQR1XS
KNS-81-FD M1j1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwMkK5OVgh|ryP MX\TRW5ITVJ?
COLO-668 M1vyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonVTWM2OD1yLkKzOlc2KM7:TR?= NVO2e3M{W0GQR1XS
C2BBe1 Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HEOmlEPTB;MD6yOlc1PyEQvF2= MVjTRW5ITVJ?
Ramos-2G6-4C10 MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfUTHVKSzVyPUCuNlY6PTRizszN M4S4eXNCVkeHUh?=
CAS-1 M1TiOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LidmlEPTB;MD6yO|A6PiEQvF2= MkP3V2FPT0WU
GOTO NXntVodzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLnTWM2OD1yLkK3PFk1KM7:TR?= MoTGV2FPT0WU
LP-1 Ml\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrQXZhKSzVyPUCuNlgxPTdizszN NHXUOm1USU6JRWK=
NCI-SNU-1 M3SxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXWTWM2OD1yLkK5OFIzKM7:TR?= NV\zfmdvW0GQR1XS
EB-3 NYPzUXV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwMkm5O|kh|ryP MV3TRW5ITVJ?
MHH-NB-11 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwM{C0NFIh|ryP MkfkV2FPT0WU
SK-N-FI MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3NPJpLUUN3ME2wMlMyPjl{IN88US=> NHfvNYhUSU6JRWK=
HCC2157 MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFyzbY1KSzVyPUCuN|M6OTNizszN MknEV2FPT0WU
SIMA MnPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofMTWM2OD1yLkO0OVgyKM7:TR?= MlSzV2FPT0WU
MDA-MB-134-VI NX\ndllTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XKZ2lEPTB;MD6zOlkzQCEQvF2= MkTLV2FPT0WU
NCI-H1694 NET4SYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjiTWM2OD1yLkO3JO69VQ>? NVW4dXVDW0GQR1XS
EHEB NVXVbIRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwM{mwPFUh|ryP Mo\1V2FPT0WU
U-266 Ml;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PNPWlEPTB;MD6zPVg1PiEQvF2= M3j6bXNCVkeHUh?=
LC-1F NXLwfXRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7MOWlKSzVyPUCuOFM4PjVizszN MkLZV2FPT0WU
SHP-77 MmnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwNEe4OVUh|ryP MlrwV2FPT0WU
LS-513 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PJ[mlEPTB;MD60PVMxPyEQvF2= NX\Ne3dWW0GQR1XS

多くの細胞株試験データを見る場合、クリックしてください

体内試験 The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

お薦めの試験操作(参考用のみ)

細胞試験:

[1]

+ 展開
  • 細胞株: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • 濃度: 0.1-100 pM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (参考用のみ)
動物試験:

[4]

+ 展開
  • 動物モデル: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • 製剤: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • 投薬量: 20 mg/kg
  • 投与方法: Administered via i.v.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
体内 順序で溶剤を入れること:
5% DMSO+5% Tween 80+ddH2O
2.5mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 853.91
化学式

C47H51NO14

CAS No. 33069-62-4
保管
別名 NSC 125973

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT03047265 Active, not recruiting Nasopharyngeal Carcinoma Sun Yat-sen University February 4, 2017 Phase 2
NCT02779855 Not yet recruiting Breast Cancer|Ductal Carcinoma|Invasive Breast Carcinoma|Invasive Ductal Breast Carcinoma H. Lee Moffitt Cancer Center and Research Institute|Amgen April 30, 2017 Phase 1|Phase 2
NCT00001426 Completed Ovarian Neoplasm National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 3, 1995 Phase 2
NCT01419548 Withdrawn Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 29, 2011 Phase 1
NCT01051934 Completed Non-Small Cell Lung Cancer|Adenocarcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 29, 2009 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • 回答:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • 問題2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • 回答:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated信号経路図

相関Microtubule Associated製品

Tags: Paclitaxelを買う | Paclitaxel ic50 | Paclitaxel供給者 | Paclitaxelを購入する | Paclitaxel費用 | Paclitaxel生産者 | オーダーPaclitaxel | Paclitaxel化学構造 | Paclitaxel分子量 | Paclitaxel代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID